Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.45 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168476 | 0.89 | KDM4E (0.57) | KDM4EMAPTNPSR1CDK2CLK1 | |
| SCHEMBL3481271 | 0.82 | KDM4E (0.55) | KDM4EMAPTNPSR1CDK2CLK1 | |
| SCHEMBL14916907 | 0.80 | KDM4E (0.54) | KDM4EKCNA5KCNH2MAPTNPSR1 | |
| SCHEMBL2168475 | 0.80 | KCNA5 (0.45) | KDM4EKCNA5KCNH2MAPTNPSR1 | |
| SCHEMBL3482350 | 0.79 | KCNA5 (0.46) | KDM4EKCNA5KCNH2MAPTNPSR1 | |
| SCHEMBL3481486 | 0.79 | KCNA5 (0.46) | KDM4EKCNA5KCNH2MAPTNPSR1 | |
| SCHEMBL2170031 | 0.79 | KCNA5 (0.46) | KDM4EKCNA5KCNH2MAPTNPSR1 | |
| SCHEMBL3482013 | 0.79 | KDM4E (0.56) | KDM4EMAPTNPSR1CDK2CLK1 | |
| SCHEMBL1386006 | 0.79 | KCNA5 (0.66) | KDM4EKCNA5KCNH2MAPTNPSR1 | |
| SCHEMBL13401016 | 0.79 | KDM4E (0.56) | KDM4EMAPTNPSR1CDK2CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4722851-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1667683-A4 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | claimed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | claimed |
| CN-1856307-A | Quinoline potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | claimed |
| EP-1667683-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030129-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692017-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1667683-A4 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| CN-1856307-A | Quinoline potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1667683-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030129-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | KCNH2, KCNJ2, KCNQ1 | KDM4E 1076/4885KCNA5 28/4885KCNH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.